Intellectual Property India Publishes Patent Application for Identification Of Tp53, A Protein Involved In Brain Tumors, As A Novel Drug Compound Using The Computer Aided Drug Designs (cadd) Method.

MUMBAI, India, June 30 -- Intellectual Property India has published a patent application (202641058015 A) filed by Saveetha Institute Of Medical And Technical Sciences on May 07, 2026, for Identification Of Tp53, A Protein Involved In Brain Tumors, As A Novel Drug Compound Using The Computer Aided Drug Designs (cadd) Method..

Inventors include Venka Tajothi Ramarao; and Deepak Nallaswamy Veeraiyan.

The application for the patent was published on June 26, 2026, under issue no. 26/2026.

Abstract: Abstract The use of computational techniques to evaluate and guide research can speed up the development of new medications for a range of human illnesses. The two primary types of computer-aided drug design (CADD) approaches are as follows: Drug design that is based on structure (SBDD) and ligand (LBDD). Although brain tumors are generally regarded as one of the "less common" cancers in terms of overall cancer incidence, their frequently aggressive nature makes them relatively high in terms of mortality. They usually rank between 15th and 20th in terms of cancer frequency, but when considering their relative lethality, they are significantly higher in terms of cancer-related deaths. Developing a prospective anti-cancer medication against the brain tumor protein, TP53, or cellular tumor antigen p53, is the aim of the current study. Chemical molecule synthesis is done using Computer Added Drug Designing (CADD) with Cheminformatics tools and software. Using molecular drug docking and toxicity assessment, the de novo structural design was verified. The de novo drug may have pharmacological action, according to the overall findings of pharmacokinetics studies like AD MET (Absorption, Distribution, Metabolism, and Excretion/Toxicity). According to the drug docking data, the newly created chemical blocks the structural and functional domains of the TP53 protein, which is mutated in brain tumors. Thus, our study has demonstrated that the de novo medication might be employed as a possible treatment for brain tumors.

Disclaimer: Curated by HT Syndication.